Skip to main content
Harriet Kluger, MD, Oncology, New Haven, CT, Yale-New Haven Hospital

HarrietMargotKlugerMD

Oncology • New Haven, CT

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Assistant Cancer Center Director for Education and Training Yale School of Medicine

Join to view full profile

Dr. Kluger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kluger's full profile

Already have an account?

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Alameda Health System-Highland Hospital
    Alameda Health System-Highland HospitalResidency, Internal Medicine, 1995 - 1996
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineResidency, Internal Medicine, 1993 - 1995
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 1992

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1995 - Present
  • CT State Medical License
    CT State Medical License 2000 - 2024
  • FL State Medical License
    FL State Medical License 2020 - 2022
  • NM State Medical License
    NM State Medical License 1993 - 2000
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States  
    Harriet Kluger, MD, JAMA Dermatology
  • Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma  
    Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Lectures

  • Updated Efficacy Studies of Anti-PD-1 Therapy and Associated Biomarkers 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • 14th Therapeutic ERCP-EUS Workshop 
    Yale CME, New Haven, Connecticut - 3/23/2012
  • Yale Cancer Center Evening Oncology Series: Melanoma 
    Yale CME, New Haven, Connecticut - 3/15/2012

Authored Content

  • Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

  • Apexigen to Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 Melanoma
    Apexigen to Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 MelanomaNovember 9th, 2021
  • The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual Meeting
    The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
  • Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight Melanoma
    Yale Cancer Center Study Shows New Strategy to Boost Immune System to Fight MelanomaOctober 19th, 2021
  • Join now to see all

Grant Support

  • Models To Predict Prognosis And Benefit From Adjuvant Therapy In Renal Cell CarciNational Cancer Institute2011–2012
  • Predicting Melanoma Response To BAY 43-9006/ChemotherapyNational Cancer Institute2005–2008

Professional Memberships

Hospital Affiliations

Dr. Harriet Kluger, Dr. Harriet Kluger, MD, Dr. H Kluger, Dr. Harriet Margot Kluger